These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31256700)

  • 1. The Role of Pharmacists in Safe Opioid Dispensing.
    Gregory T; Gregory L
    J Pharm Pract; 2020 Dec; 33(6):856-862. PubMed ID: 31256700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The opioid crisis: Origins, trends, policies, and the roles of pharmacists.
    Chisholm-Burns MA; Spivey CA; Sherwin E; Wheeler J; Hohmeier K
    Am J Health Syst Pharm; 2019 Mar; 76(7):424-435. PubMed ID: 31361827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacists' role in addressing opioid abuse, addiction, and diversion.
    J Am Pharm Assoc (2003); 2014; 54(1):e5-15. PubMed ID: 24257743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies and policies to address the opioid epidemic: A case study of Ohio.
    Penm J; MacKinnon NJ; Boone JM; Ciaccia A; McNamee C; Winstanley EL
    J Am Pharm Assoc (2003); 2017; 57(2S):S148-S153. PubMed ID: 28189539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising roles for pharmacists in addressing the U.S. opioid crisis.
    Compton WM; Jones CM; Stein JB; Wargo EM
    Res Social Adm Pharm; 2019 Aug; 15(8):910-916. PubMed ID: 29325708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems.
    Cobaugh DJ; Gainor C; Gaston CL; Kwong TC; Magnani B; McPherson ML; Painter JT; Krenzelok EP
    Am J Health Syst Pharm; 2014 Sep; 71(18):1539-54. PubMed ID: 25174015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of opioid crisis and the role of pharmacist-led interventions.
    Sanyal C
    J Am Pharm Assoc (2003); 2021; 61(3):e70-e74. PubMed ID: 33279425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse and diversion.
    Nalamachu SR; Shah B
    Postgrad Med; 2022 May; 134(4):388-394. PubMed ID: 30025214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
    Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
    J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and Misuse of Opioids in Maine: Results From Pharmacists, the Prescription Monitoring, and the Diversion Alert Programs.
    Piper BJ; Desrosiers CE; Lipovsky JW; Rodney MA; Baker RP; McCall KL; Nichols SD; Martin SL
    J Stud Alcohol Drugs; 2016 Jul; 77(4):556-65. PubMed ID: 27340958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid Misuse and Overdose: Changes in Pharmacist Practices and Outcomes.
    Eukel H; Steig J; Frenzel O; Skoy E; Werremeyer A; Strand M
    J Contin Educ Health Prof; 2020; 40(4):242-247. PubMed ID: 33284175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs.
    Hahn KL
    Am Health Drug Benefits; 2011 Mar; 4(2):107-14. PubMed ID: 25126342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.
    Salwan A; Hagemeier NE; Tudiver F; Dowling-McClay K; Foster KN; Arnold J; Alamian A; Pack RP
    J Am Pharm Assoc (2003); 2020; 60(6):e173-e178. PubMed ID: 32669219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
    Haggerty LC; Gatewood SS; Goode JKR
    J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe Opioid Use, Storage, and Disposal Strategies in Cancer Pain Management.
    Reddy A; de la Cruz M
    Oncologist; 2019 Nov; 24(11):1410-1415. PubMed ID: 31097618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1.
    Kaye AD; Jones MR; Kaye AM; Ripoll JG; Galan V; Beakley BD; Calixto F; Bolden JL; Urman RD; Manchikanti L
    Pain Physician; 2017 Feb; 20(2S):S93-S109. PubMed ID: 28226333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of abuse-deterrent opioids and recommendations for practical patient care.
    Adler JA; Mallick-Searle T
    J Multidiscip Healthc; 2018; 11():323-332. PubMed ID: 30026658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.